Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation

Korábbi kezelés

• type 1 diabetes, or previous diabetic ketoacidosis
• planned surgery or other interventional procedure within 3 months

Más betegség

• diagnosed with atrial fibrillation secondary to reversible causes (such as hyperthyroidism, acute infection, etc.)
• severe structural heart disease (hypertrophic cardiomyopathy, rheumatic heart disease, dilated cardiomyopathy, etc.)
• severe hypoglycemia or genitourinary infection in the past 12 months
• other arrhythmias mandating anti-arrhythmic drug therapy
• active infection
• other condition unsuitable to participate in this study judged by investigators

Laborértékek

• currently take sodium-glucose co-transporter 2 inhibitors
• have the following Class I indications for sodium-glucose co-transporter 2 inhibitors: i. type 2 diabetes ii. history of heart failure (HF), including HF with reduced ejection fraction, mildly reduced ejection fraction, and preserved ejection fraction iii. chronic kidney disease with eGFR=20-60 ml/min/1.73m2
• have the following contraindication of sodium-glucose co-transporter 2 inhibitors: i. previous allergic reactions to dapagliflozin ii. end-stage renal failure or dialysis

Egyéb

• diagnosed with persistent atrial fibrillation longer than 5 years or left atrial anterior-posterior diameter ≥ 50mm
• hypovolemia or hypotension
• have intracardiac thrombus
• unable to give informed consent
• women of childbearing potential
• currently enrolled in another clinical study

• age between 18-80 years
• diagnosed with persistent atrial fibrillation based on ECG or Holter
• planned initial catheter ablation for atrial fibrillation
• have the capacity to understand and sign an informed consent form.